Phase Forward appointed long-time employee Michael Owings to the new role of chief privacy officer. Owings will oversee all privacy and data protection processes affecting Phase Forward’s customers and employees, and ensure compliance with all relevant regulations. He will also continue his duties as vice president, quality and regulatory compliance—a title he’s held since 2004.
Owings has worked at Phase Forward for nine years, serving in quality affairs and regulatory management roles before becoming vice president. Before joining Phase Forward, he held various positions at Copley Pharmaceutical, Procept and Marion Merrell Dow (HMR/Aventis).
Other personnel news from the industry:
Seattle, Wa.-based biotechnology company Dendreon named former Bayer executive Hans Bishop as chief operating officer. Bishop most recently served as president of Bayer’s specialty medicine business and was responsible for oncology, hematology and neurology products.
Oncolytics Biotech announced the appointment of Alan Warrander to the role of senior vice president, global licensing and business development. Prior to this appointment, Warrander held a number of progressively senior positions in the pharmaceutical industry, most recently as director, global licensing, AstraZeneca. He subsequently served as senior vice president, life sciences, at Wood Mackenzie, providing partnering support and advice to a range of clients on global licensing, merger and acquisition and financing projects. Most recently, Warrander worked as an independent consultant for a number of biotechnology clients.
Sanofi-aventis and its wholly-owned subsidiary BiPar Sciences announced changes to the executive management team at BiPar Sciences. BiPar CEO and president Hoyoung Huh, M.D., Ph.D. will take on a broader role in the sanofi-aventis organization as chairman of the board of directors of BiPar, as well as chair of the newly formed BiPar innovation board. Sanofi-aventis appointed Atul Dhir, M.D., Ph.D. as CEO of BiPar Sciences. Prior to joining BiPar, Dhir was a senior executive at US Oncology, and he previously served as a vice president of the healthcare division of Monsanto and as a consultant with McKinsey and Company.
Chiltern International appointed Sharon Moore, M.D. as executive vice president, global quality and medical affairs. Prior to joining Chiltern, Sharon served as a pharmacovigilance physician and practiced medicine, served as an investigator, was a member of an Institutional Review Board and authored several publications. She joined CTMS, a U.S. CRO, in 1998. Sharon has served with Chiltern since the acquisition of CTMS in 2007 as global head of quality assurance and executive director, medical affairs.
Gwathmey, a pre-clinical CRO and biotechnology company, appointed Rosalie Dunn, Ph.D., as CEO. Prior to joining Gwathmey, Dunn managed multimillion-dollar portfolios for the National Institutes of Health, which included cardiovascular devices and technologies, clinical studies, imaging applications, development of new animal models, bioengineering projects, sleep research, computer models, atherosclerotic plaque detection and classification, antiarrhythmic treatments and devices, telemetry systems and device miniaturization.